pdia3-protein
Overview
The PDIA3 gene encodes protein disulfide-isomerase A3 (also known as ERP57, ERp57, or protein disulfide isomerase family A member 3), a 57-kDa protein that resides primarily in the endoplasmic reticulum (ER). PDIA3 belongs to the protein disulfide isomerase (PDI) family, a group of oxidoreductases responsible for managing protein folding, disulfide bond formation, and endoplasmic reticulum quality control. As an ER-resident chaperone protein, PDIA3 functions at the intersection of multiple cellular stress responses, including unfolded protein response (UPR) activation, calcium homeostasis, and ER-associated degradation (ERAD). The protein contains two catalytically active thioredoxin-like domains (a and a' domains) flanking an inhibitory b domain, as well as a b' domain that contributes to substrate binding and client protein interactions.
Function/Biology
PDIA3 executes multiple critical functions in maintaining ER proteostasis. As a disulfide isomerase, it catalyzes the formation, reduction, and rearrangement of disulfide bonds in nascent proteins, facilitating proper protein folding. The enzyme actively participates in the ERAD pathway by facilitating retrotranslocation of misfolded proteins across the ER membrane and delivering them to proteasomal degradation. Beyond canonical PDI functions, PDIA3 interacts with several protein families including calnexin and calreticulin, major ER lectins that recognize improperly glycosylated proteins. This collaboration ensures productive folding pathways for glycoproteins.
...pdia3-protein
Overview
The PDIA3 gene encodes protein disulfide-isomerase A3 (also known as ERP57, ERp57, or protein disulfide isomerase family A member 3), a 57-kDa protein that resides primarily in the endoplasmic reticulum (ER). PDIA3 belongs to the protein disulfide isomerase (PDI) family, a group of oxidoreductases responsible for managing protein folding, disulfide bond formation, and endoplasmic reticulum quality control. As an ER-resident chaperone protein, PDIA3 functions at the intersection of multiple cellular stress responses, including unfolded protein response (UPR) activation, calcium homeostasis, and ER-associated degradation (ERAD). The protein contains two catalytically active thioredoxin-like domains (a and a' domains) flanking an inhibitory b domain, as well as a b' domain that contributes to substrate binding and client protein interactions.
Function/Biology
PDIA3 executes multiple critical functions in maintaining ER proteostasis. As a disulfide isomerase, it catalyzes the formation, reduction, and rearrangement of disulfide bonds in nascent proteins, facilitating proper protein folding. The enzyme actively participates in the ERAD pathway by facilitating retrotranslocation of misfolded proteins across the ER membrane and delivering them to proteasomal degradation. Beyond canonical PDI functions, PDIA3 interacts with several protein families including calnexin and calreticulin, major ER lectins that recognize improperly glycosylated proteins. This collaboration ensures productive folding pathways for glycoproteins.
PDIA3 also regulates calcium signaling within the ER lumen, influences ER stress sensor activation, and modulates inflammatory responses through interactions with toll-like receptors. The protein demonstrates tissue-specific expression patterns, with particularly high levels in the central nervous system and tissues with high secretory capacity. Additionally, PDIA3 can translocate to the cell surface and extracellular space under certain conditions, where it adopts signaling functions distinct from its canonical ER role.
Role in Neurodegeneration
Dysregulation of PDIA3 and ER proteostasis dysfunction are implicated in multiple neurodegenerative diseases. In Alzheimer's disease, accumulation of misfolded amyloid-beta (Aβ) and tau proteins triggers sustained ER stress and UPR activation, creating elevated demand for PDIA3-mediated protein folding capacity. Inadequate PDIA3 function contributes to protein aggregation and neuronal death. Similarly, in Parkinson's disease, misfolded alpha-synuclein accumulation overwhelms ER quality control mechanisms; PDIA3 dysfunction exacerbates proteostatic stress and facilitates pathological alpha-synuclein aggregation.
In ALS, both TDP-43 and FUS proteins exhibit aberrant localization and aggregation patterns partly attributable to impaired ER proteostasis. PDIA3 dysregulation compromises the clearance of these pathogenic species. Huntington's disease pathology involves polyglutamine-expanded huntingtin protein accumulation, which similarly depends on ER chaperone function for appropriate handling. Additionally, genetic variants and altered PDIA3 expression levels have been associated with increased susceptibility to multiple neurodegenerative conditions, suggesting PDIA3 functions as a genetic risk modifier.
Molecular Mechanisms
PDIA3 operates through several interconnected mechanisms in neurodegeneration. During proteostatic stress, PDIA3 expression increases through ER stress-induced transcription factors including ATF4 and XBP1, components of the UPR. However, chronic neuroinflammation and persistent protein aggregates can overwhelm PDIA3 capacity, leading to PDIA3 oxidation, inactivation, and sequestration within protein aggregates. Oxidative stress—prominent in neurodegenerative diseases—directly damages PDIA3's catalytic cysteines, reducing enzymatic activity.
PDIA3 specifically interacts with prion-like proteins through its substrate-binding domain, influencing their conformational fate. In cells expressing pathogenic proteins, PDIA3 can promote either productive refolding or proteasomal targeting depending on protein-specific factors and cellular context. The protein also regulates NLRP3 inflammasome activation by controlling ER calcium levels and caspase-1 activation, thereby modulating neuroinflammatory cascades central to neurodegeneration.
Clinical/Research Significance
PDIA3 represents both a biomarker and therapeutic target in neurodegeneration research. Cerebrospinal fluid and plasma PDIA3 levels correlate with ER stress burden and may serve as disease progression indicators. Pharmacological enhancement of PDIA3 expression or activity through approaches targeting ER stress pathways shows promise in preclinical models. PDIA3 overexpression studies demonstrate neuroprotective effects against amyloid toxicity, alpha-synuclein aggregation, and polyglutamine toxicity, supporting therapeutic potential.